Mafalda Santos Melo

Dr. Mafalda Santos Melo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMafalda Santos Melo
Mafalda Santos Melo
MRMariana Ribeiro
Mariana Ribeiro
Paulo Filipe SilvaPaulo Filipe Silva
Paulo Filipe Silva
SVSusana Valente
Susana Valente
FAFilipe da Costa Alves
Filipe da Costa Alves
JOJorge Oliveira
Jorge Oliveira
The application of whole-exome sequencing (WES) for diagnostic purposes has the potential to unravel secondary findings unrelated with the primary reason of testing. Some of those might be of high clinical utility and comprise disease-causing variants in genes, related to life-threatening and clinically actionable diseases. Clarifying the allelic frequencies of such variants in specific populations is a crucial step for the large-scale deployment of genomic medicine. We analysed medically relevant variants in the 81 genes from the American College of Medical Genetics and Genomics (ACMG) v3.2 list of actionable loci, using WES data from a diagnostic laboratory cohort of 3972 persons, tentatively resampled to represent the Portuguese population geographic distribution. We identified medically actionable variants in 6.2% of our cohort, distributed across several disease domains: cardiovascular disorders (3.0%), cancer predisposition (2.0%), miscellaneous disorders (1.1%), and metabolic disorders (0.1%). Additionally, we estimated a frequency of heterozygotes for recessive disease alleles of 11.1%. Overall, our results suggest that medically actionable findings can be identified in approximately 6.2% of persons from our population. This is the first study estimating medically actionable findings in Portugal. These results provide valuable insight for patients, healthcare providers, and policymakers involved in advancing genomic medicine at the national and international level.

21 March 2022 in Genetics in Medicine
Verified
Journal Article
Closed access
MMMafalda Santos Melo
Mafalda Santos Melo
Jorge M. A. OliveiraJorge M. A. Oliveira
Jorge M. A. Oliveira
DADiana Antunes
Diana Antunes

17 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMafalda Santos Melo
Mafalda Santos Melo
MRMariana Ribeiro
Mariana Ribeiro
Paulo Filipe SilvaPaulo Filipe Silva
Paulo Filipe Silva
SVSusana Valente
Susana Valente
FAFilipe da Costa Alves
Filipe da Costa Alves
JOJorge Oliveira
Jorge Oliveira
The application of whole-exome sequencing (WES) for diagnostic purposes has the potential to unravel secondary findings unrelated with the primary reason of testing. Some of those might be of high clinical utility and comprise disease-causing variants in genes, related to lifethreatening and clinically actionable diseases. Clarifying the allelic frequencies of such variants in specific populations is a crucial step for the large-scale deployment of genomic medicine. We analysed medically relevant variants in the 81 genes from the American College of Medical Genetics and Genomics (ACMG) v3.2 list of actionable loci, using WES data from a diagnostic laboratory cohort of 3,972 persons, tentatively resampled to represent the Portuguese population geographic distribution. We identified medically actionable variants in 6.2% of our cohort, distributed across several disease domains: cardiovascular disorders (3.0%), cancer predisposition (2.0%), miscellaneous disorders (1.1%), and metabolic disorders (0.1%). Additionally, we estimated a frequency of heterozygotes for recessive disease alleles of 11.1%. Overall, our results suggest that medically actionable findings can be identified in approximately 6.2% of persons from our population. This is the first study estimating medically actionable findings in Portugal. These results provide valuable insight for patients, healthcare providers, and policymakers involved in advancing genomic medicine at the national and international level.